Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

7.070 USD +0.170 (+2.46%)
Streaming Delayed Price Updated: 10:36 AM EST, Jan 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Ardelyx Inc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga ... 
Tags AEO ABEO Trading Ideas
From Benzinga
Why Ardelyx Shares Are Sinking Today
The clinical-stage biotech's stock gave back about half of Tuesday's big gain in Wednesday morning trading. 
Tags ARDX Market News
From Motley Fool
10 Healthcare Stocks Moving In Wednesday's Pre-Market Session
Gainers OpGen, Inc. (NASDAQ: OPGN) stock surged 68.4% to $10.98 during Wednesday's pre-market session. The market cap stands ... 
Tags Market News Pre/Market Outlook KZR
From Benzinga
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags Pre/Market Outlook RIGL SRPT
From Benzinga
66 Biggest Movers From Yesterday
Gainers Ardelyx, Inc. (NASDAQ: ARDX) shares rose 71.2% to close at $5.82 on Tuesday after the company's pivotal phase 3 ... 
Tags RYAM HEBT RDHL
From Benzinga
Noteworthy Tuesday Option Activity: ARDX, TPB, IRBT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ardelyx Inc (ARDX), where a total of 2,457 contracts have traded so far, representing... 
Tags Stocks
From Market News Video
Why Are Shares Of Ardelyx Ripping Higher?
Shares of Ardelyx Inc (NASDAQ: ARDX) wereadvancing strongly on above-average volume Tuesdayfollowing a clinical trial ... 
Tags Trading Ideas General News
From Benzinga
Mid-Afternoon Market Update: Dow Down 350 Points; MAM Software Shares Surge Following Acquisition News
Toward the end of trading Tuesday, the Dow traded down 1.33% to 26053.06 while the NASDAQ fell 1.31% to 7,858.22. The S&P also fell, ... 
Tags NSSC Market News Earnings
From Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cidara Therapeutics, Inc. (NASDAQ: CDTX) shares climbed 53% to $2.57 after the company announced it has formed a ... 
Tags HEBT MAT GV
From Benzinga
Mid-Day Market Update: Napco Security Technologies Drops After Q4 Results; Cidara Therapeutics Shares Jump
Midway through trading Tuesday, the Dow traded down 1.31% to 26057.05 while the NASDAQ fell 0.94% to 7888.18. The S&P also fell, ... 
Tags Intraday Update Markets Commodities
From Benzinga
Why Ardelyx Is Soaring Today
Shares jump after the clinical-stage biotech reports encouraging results from an important late-stage trial. 
Tags Market News ARDX
From Motley Fool
Mid-Morning Market Update: Markets Open Lower; Conn's Beats Q2 Expectations
Following the market opening Tuesday, the Dow traded down 1.46% to 26017.89 while the NASDAQ fell 1.06% to 7878.76. The S&P also ... 
Tags News IIPR ARDS
From Benzinga
32 Healthcare Stocks Moving In Tuesday's Pre-Market Session
Gainers Cidara Therapeutics, Inc. (NASDAQ: CDTX) stock increased by 68.5% to $2.83 during Tuesday's pre-market session. The ... 
Tags SLS GRFS ALC
From Benzinga
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
The primary and all key secondary endpoints were met. 
From PR Newswire
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will... 
From PR Newswire
Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
FDA activity remained brisk in August. The FDA gave its nod for a majority of drugs that came up for review, although Vanda ... 
Tags VNDA SRPT FDA
From Benzinga
55 Biggest Movers From Yesterday
Gainers SCWorx Corp. (NASDAQ: WORX) shares rose 71.1% to close at $3.73 on Tuesday. Cheetah Mobile Inc. (NYSE: CMCM) jumped ... 
Tags Market News IBIO IPWR
From Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cemtrex, Inc. (NASDAQ: CETX) shares rose 71.1% to $2.5999 after the company reported Q3 sales up from last year. iBio, ... 
Tags News Mid/Day Movers HGV
From Benzinga
72 Biggest Movers From Yesterday
Gainers DPW Holdings, Inc. (NYSE: DPW) shares jumped 133% to close at $4.80 on Monday after the company announced that its ... 
Tags HOV EIDX GLOB
From Benzinga
Notable Monday Option Activity: CRY, ARDX, LULU
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CryoLife, Inc. (CRY), where a total volume of 1,062 contracts has been traded thus... 
Tags Stocks
From Market News Video
48 Stocks Moving In Monday's Mid-Day Session
Gainers DPW Holdings, Inc. (NYSE: DPW) shares climbed 262.6% to $7.47 after the company announced that its subsidiary, Digital ... 
Tags Biotechnology NSPR PACD
From Benzinga
5 Biggest New Drug Approvals Potentially on the Way in 2019
FDA approvals for these drugs could translate to billions of dollars for a few companies. 
Tags XLRN ITCI ARDX
From Motley Fool
60 Biggest Movers From Friday
Gainers Plus Therapeutics, Inc. (NASDAQ: PSTV) shares jumped 272.2% to close at $14.44 on Friday after the company reported Q2 ... 
Tags RKDA News VAL
From Benzinga
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
AMPLIFY clinical trial to read out 3Q19 
From PR Newswire
Knight Announces Filing of New Drug Submission for Ibsrela™ in Canada
Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Ibsrela™ (tenapanor) has been accepted for... 
From GlobeNewswire News Releases
SPSM's Holdings Could Mean 18% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today announced... 
From PR Newswire
Analysts Expect VTHR Will Reach $147
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Two Pivotal Phase 3 readouts in 2H 2019 
From PR Newswire
Analysts Anticipate 13% Gains Ahead For VTWO
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.